{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T18:47:44Z","timestamp":1780598864967,"version":"3.54.1"},"reference-count":93,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1016\/j.autrev.2020.102587","type":"journal-article","created":{"date-parts":[[2020,6,14]],"date-time":"2020-06-14T09:42:04Z","timestamp":1592127724000},"page":"102587","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":33,"title":["Sarcoidosis related to checkpoint and BRAF\/MEK inhibitors in melanoma"],"prefix":"10.1016","volume":"19","author":[{"given":"Manuel","family":"Rubio-Rivas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catarina","family":"Moreira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Marcoval","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.autrev.2020.102587_bb0005","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1038\/bjc.1974.64","article-title":"The incidence of malignant tumours in patients with respiratory sarcoidosis","volume":"29","author":"Brincker","year":"1974","journal-title":"Br J Cancer"},{"key":"10.1016\/j.autrev.2020.102587_bb0010","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1097\/00007611-198509000-00027","article-title":"Sarcoidosis: a cause of bilateral hilar lymphadenopathy after excision of malignant melanoma of the arm","volume":"78","author":"Rubinstein","year":"1985","journal-title":"South Med J"},{"key":"10.1016\/j.autrev.2020.102587_bb0015","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1038\/bjc.1986.199","article-title":"The sarcoidosis-lymphoma syndrome","volume":"54","author":"Brincker","year":"1986","journal-title":"Br J Cancer"},{"key":"10.1016\/j.autrev.2020.102587_bb0020","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1002\/mpo.2950150207","article-title":"Solid tumors preceding or following sarcoidosis","volume":"15","author":"Brincker","year":"1987","journal-title":"Med Pediatr Oncol"},{"key":"10.1016\/j.autrev.2020.102587_bb0025","first-page":"31","article-title":"Coexistence of sarcoidosis and malignant disease: causality or coincidence?","volume":"6","author":"Brincker","year":"1989","journal-title":"Sarcoidosis"},{"key":"10.1016\/j.autrev.2020.102587_bb0030","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1378\/chest.98.5.1300","article-title":"The malignancy-sarcoidosis syndrome","volume":"98","author":"Suen","year":"1990","journal-title":"Chest"},{"key":"10.1016\/j.autrev.2020.102587_bb0035","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1136\/thx.52.10.892","article-title":"Risk of malignant neoplasms in patients with pulmonary sarcoidosis","volume":"52","author":"Seersholm","year":"1997","journal-title":"Thorax"},{"key":"10.1016\/j.autrev.2020.102587_bb0040","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1183\/09031936.98.12040906","article-title":"Sarcoidosis and cancer revisited: a long-term follow-up study of 555 Danish sarcoidosis patients","volume":"12","author":"Romer","year":"1998","journal-title":"Eur Respir J"},{"key":"10.1016\/j.autrev.2020.102587_bb0045","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1002\/(SICI)1097-0142(19980715)83:2<337::AID-CNCR18>3.0.CO;2-U","article-title":"Sarcoidosis and testicular carcinoma","volume":"83","author":"Rayson","year":"1998","journal-title":"Cancer"},{"key":"10.1016\/j.autrev.2020.102587_bb0050","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1164\/ajrccm.160.5.9904045","article-title":"Increased risk for cancer following sarcoidosis","volume":"160","author":"Askling","year":"1999","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.autrev.2020.102587_bb0055","first-page":"95","article-title":"Association between sarcoidosis and testicular carcinoma: a diagnostic pitfall","volume":"24","author":"Paparel","year":"2007","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"10.1016\/j.autrev.2020.102587_bb0060","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.clindermatol.2007.03.010","article-title":"Sarcoidosis and malignancy","volume":"25","author":"Cohen","year":"2007","journal-title":"Clin Dermatol"},{"key":"10.1016\/j.autrev.2020.102587_bb0065","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1159\/000213245","article-title":"Sarcoidosis and melanoma: a referral center study of 1,199 cases","volume":"219","author":"Seve","year":"2009","journal-title":"Dermatology"},{"key":"10.1016\/j.autrev.2020.102587_bb0070","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1111\/j.1600-0560.2011.01702.x","article-title":"Alpha-interferon induced sarcoidosis mimicking metastatic melanoma","volume":"38","author":"North","year":"2011","journal-title":"J Cutan Pathol"},{"key":"10.1016\/j.autrev.2020.102587_bb0075","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1136\/thx.2004.024018","article-title":"Increased disease activity in a patient with sarcoidosis after high dose interleukin 2 treatment for metastatic renal cancer","volume":"60","author":"Logan","year":"2005","journal-title":"Thorax"},{"key":"10.1016\/j.autrev.2020.102587_bb0080","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2020.102587_bb0085","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1056\/NEJMoa1103782","article-title":"Improved survival with vemurafenib in melanoma with BRAF V600E mutation","volume":"364","author":"Chapman","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2020.102587_bb0090","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1056\/NEJMoa1112302","article-title":"Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib","volume":"366","author":"Sosman","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2020.102587_bb0095","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1056\/NEJMoa1414428","article-title":"Nivolumab and ipilimumab versus ipilimumab in untreated melanoma","volume":"372","author":"Postow","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2020.102587_bb0100","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined nivolumab and ipilimumab or monotherapy in untreated melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2020.102587_bb0105","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","article-title":"Pembrolizumab versus Ipilimumab in Advanced Melanoma","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2020.102587_bb0110","first-page":"102454","article-title":"Isolated autoimmune adrenocorticotropic hormone deficiency: from a rare disease to the dominant cause of adrenal insufficiency related to check point inhibitors","volume":"12","author":"Percik","year":"2019","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2020.102587_bb0115","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.currproblcancer.2016.12.001","article-title":"Cutaneous adverse effects of the immune checkpoint inhibitors","volume":"41","author":"Collins","year":"2017","journal-title":"Curr Probl Cancer"},{"key":"10.1016\/j.autrev.2020.102587_bb0120","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1159\/000161122","article-title":"Anti-CTLA4 monoclonal antibody induced sarcoidosis in a metastatic melanoma patient","volume":"218","author":"Eckert","year":"2009","journal-title":"Dermatology"},{"issue":"197","key":"10.1016\/j.autrev.2020.102587_bb0125","doi-asserted-by":"crossref","first-page":"992","DOI":"10.2214\/AJR.10.6198","article-title":"Radiologic Manifestations of immune-related adverse events in patients with metastatic melanoma undergoing anti-CTLA-4 antibody therapy","volume":"12","author":"Bronstein","year":"2011","journal-title":"Am J Roentegenol"},{"key":"10.1016\/j.autrev.2020.102587_bb0130","first-page":"1355","article-title":"Sarcoidosis in a patient with metastatic melanoma sequentially treated with anti-CTLA-4 monoclonal antibody and selective BRAF inhibitor","volume":"32","author":"Wilgenhof","year":"2012","journal-title":"Anticancer Res"},{"key":"10.1016\/j.autrev.2020.102587_bb0135","doi-asserted-by":"crossref","first-page":"e7","DOI":"10.1200\/JCO.2011.37.9693","article-title":"Ipilimumab-induced sarcoidosis in a patient with metastatic melanoma undergoing complete remission","volume":"30","author":"Vogel","year":"2012","journal-title":"J Clin Oncol"},{"issue":"30","key":"10.1016\/j.autrev.2020.102587_bb0140","doi-asserted-by":"crossref","first-page":"e156","DOI":"10.1200\/JCO.2011.39.3298","article-title":"Pulmonary Sarcoid-Like Granulomatosis Induced by Ipilimumab","volume":"10","author":"Berthod","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.autrev.2020.102587_bb0145","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1183\/09031936.00107912","article-title":"Sarcoidosis complicating anti-cytotoxic T-lymphocyte associated antigen-4 monoclonal antibody biotherapy","volume":"41","author":"Tissot","year":"2011","journal-title":"Eur Respir J"},{"key":"10.1016\/j.autrev.2020.102587_bb0150","doi-asserted-by":"crossref","first-page":"e272","DOI":"10.1016\/j.jaad.2013.07.028","article-title":"Cutaneous and pulmonary sarcoidosis-like reaction associated with ipilimumab","volume":"69","author":"Reule","year":"2013","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.autrev.2020.102587_bb0155","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1159\/000362614","article-title":"New-onset mediastinal and central nervous system sarcoidosis in a patient with metastatic melanoma undergoing CTLA4 monoclonal antibody treatment","volume":"37","author":"Murphy","year":"2014","journal-title":"Oncol Res Treat"},{"key":"10.1016\/j.autrev.2020.102587_bb0160","article-title":"Late development of splenic sarcoidosis-like lesions in a patient with metastatic melanoma and long-lasting clinical response to ipilimumab","volume":"3","author":"Andersen","year":"2014","journal-title":"Onco Immunol"},{"key":"10.1016\/j.autrev.2020.102587_bb0165","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1097\/RLU.0b013e31828da691","article-title":"Ipilimumab-induced Immunomediated adverse events, posible pitfalls in 18F-FDG PET\/CT interpretation","volume":"39","author":"Gilardi","year":"2014","journal-title":"Clin Nucl Med"},{"key":"10.1016\/j.autrev.2020.102587_bb0170","doi-asserted-by":"crossref","first-page":"e32","DOI":"10.1200\/JCO.2013.49.7735","article-title":"Antitumor granuloma formation by CD4+ T cells in a patient with rapidly progressive melanoma experiencing spiking fevers, neuropathy, and other immune-related toxicity after treatment with Ipilimumab","volume":"33","author":"Luke","year":"2015","journal-title":"J Clin Oncol"},{"issue":"36","key":"10.1016\/j.autrev.2020.102587_bb0175","article-title":"Ipilimumab therapy for melanoma: a mimic of leptomeningeal metastasis","volume":"12","author":"Ali","year":"2015","journal-title":"Am J Neuroradiol"},{"key":"10.1016\/j.autrev.2020.102587_bb0180","first-page":"1","article-title":"Ipilimumab-induced granulomatous disease occurring simultaneously with disease progression in a patient with metastatic melanoma","volume":"4","author":"Toumeh","year":"2015","journal-title":"Am J Ther"},{"key":"10.1016\/j.autrev.2020.102587_bb0185","first-page":"1","article-title":"Systemic inflammation in a melanoma patient treated with immune checkpoint inhibitors \u2014 an autopsy study","volume":"4","author":"Koelzer","year":"2016","journal-title":"J Immunother"},{"key":"10.1016\/j.autrev.2020.102587_bb0190","first-page":"1","article-title":"Sarcoidosis in the setting of combination ipilimumab and nivolumab immunotherapy\u00a0: a case report & review of the literature","volume":"4","author":"Reuss","year":"2016","journal-title":"J Immunother"},{"key":"10.1016\/j.autrev.2020.102587_bb0195","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1111\/dth.12380","article-title":"Cutaneous sarcoidosis in a melanoma patient under Ipilimumab therapy","volume":"29","author":"Martinez","year":"2016","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.autrev.2020.102587_bb0200","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1111\/bjd.14674","article-title":"Foreign body reaction triggered by CTLA-4 blockade 25 years after dermal filler injection, a case report","volume":"75","author":"Bisschop","year":"2016","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.autrev.2020.102587_bb0205","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1177\/1078155216667635","article-title":"Sarcoidosis-like syndrome and lymphadenopathy due to checkpoint inhibitors","volume":"23","author":"Firwana","year":"2017","journal-title":"J Oncol Pharm Pract"},{"key":"10.1016\/j.autrev.2020.102587_bb0210","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1097\/CJI.0000000000000181","article-title":"Sarcoidosis following anti-PD-1 and anti-CTLA-4 therapy for metastatic melanoma","volume":"40","author":"Reddy","year":"2017","journal-title":"J Immunother"},{"key":"10.1016\/j.autrev.2020.102587_bb0215","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1111\/ijd.13540","article-title":"Histopathological aspects of cutaneous erythematous-papular eruptions induced by immune checkpoint inhibitors for the treatment of metastatic melanoma","volume":"56","author":"Perret","year":"2017","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.autrev.2020.102587_bb0220","first-page":"13","article-title":"Diffuse granulomatous panniculitis associated with anti PD-1 antibody therapy","volume":"4","author":"Jiang","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.autrev.2020.102587_bb0225","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1159\/000491599","article-title":"Neurosarcoidosis following immune checkpoint inhibition","volume":"11","author":"Dunn-Pirio","year":"2018","journal-title":"Case Rep Oncol"},{"key":"10.1016\/j.autrev.2020.102587_bb0230","first-page":"77","article-title":"Delayed onset of neurosarcoidosis after concurrent ipilimumab\/nivolumab therapy","volume":"6","author":"Tan","year":"2018","journal-title":"J Immunother"},{"key":"10.1016\/j.autrev.2020.102587_bb0235","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/j.rmr.2018.08.003","article-title":"Granulomatose sarco\u00efdosique survenant sous inhibiteurs de point de contr\u00f4le immunitaire","volume":"35","author":"Faviez","year":"2018","journal-title":"Rev Mal Respir"},{"key":"10.1016\/j.autrev.2020.102587_bb0240","doi-asserted-by":"crossref","first-page":"e379","DOI":"10.1097\/MJT.0000000000000545","article-title":"Ipilimumab-induced sarcoidosis and thyroiditis","volume":"25","author":"Nandavaram","year":"2018","journal-title":"Am J Ther"},{"key":"10.1016\/j.autrev.2020.102587_bb0245","first-page":"1","article-title":"Granulomatous\/sarcoid-like lesions associated with checkpoint inhibitors\u00a0: a marker of therapy response in a subset of melanoma patients","volume":"6","author":"Tetzlaff","year":"2018","journal-title":"J Immunother"},{"key":"10.1016\/j.autrev.2020.102587_bb0250","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1111\/cup.13267","article-title":"Granulomatous dermatitis associated with ipilimumab therapy (Ipilimumab associated granulomatous dermatitis)","volume":"45","author":"Kubicki","year":"2018","journal-title":"J Cutan Pathol"},{"key":"10.1016\/j.autrev.2020.102587_bb0255","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.humpath.2019.07.001","article-title":"Immune checkpoint blocker-related sarcoid-like granulomatous inflammation: a rare adverse event detected in lymph node aspiration cytology of patients treated for advanced malignant melanoma","volume":"91","author":"Rodriguez","year":"2019","journal-title":"Hum Pathol"},{"key":"10.1016\/j.autrev.2020.102587_bb0260","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.ad.2017.11.021","article-title":"Granulomatous reaction in a patient with metastatic melanoma treated with Ipilimumab\u00a0: first case reported with isolated cutaneous findings","volume":"110","author":"Cervantes","year":"2019","journal-title":"Actas Dermosifiliogr"},{"key":"10.1016\/j.autrev.2020.102587_bb0265","first-page":"6702870","article-title":"Exclusive cutaneous and subcutaneous Sarcoidal granulomatous inflammation due to immune checkpoint inhibitors: report of two cases with unusual manifestations and review of the literature","volume":"2019","author":"Mobini","year":"2019","journal-title":"Case Rep Dermatol Med"},{"key":"10.1016\/j.autrev.2020.102587_bb0270","doi-asserted-by":"crossref","first-page":"e133","DOI":"10.1016\/j.chest.2015.10.082","article-title":"Nivolumab-induced sarcoid-like granulomatous reaction in a patient with advanced melanoma","volume":"149","author":"Danlos","year":"2016","journal-title":"Chest"},{"key":"10.1016\/j.autrev.2020.102587_bb0275","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1159\/000492383","article-title":"Pulmonary sarcoid-like granulomatosis induced by nivolumab","volume":"11","author":"Montiaudi\u00e9","year":"2018","journal-title":"Case Rep Oncol"},{"key":"10.1016\/j.autrev.2020.102587_bb0280","first-page":"92","article-title":"Multifocal choroiditis as the first sign of systemic sarco\u00efdosis associated with pembrolizumab","volume":"5","author":"Qu-Knafo","year":"2016","journal-title":"Am J Ophtalmol"},{"key":"10.1016\/j.autrev.2020.102587_bb0285","first-page":"8","article-title":"Sarcoidosis post-anti-PD-1 therapy, mimicking relapse of metastatic melanoma in a patient undergoing complete remission","author":"Yatim","year":"2017","journal-title":"Rev Med Interne"},{"key":"10.1016\/j.autrev.2020.102587_bb0290","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1111\/1756-185X.13076","article-title":"Immunotherapy-induced sarcoidosis in patients with melanoma treated with PD-1 checkpoint inhibitors: case series and immunophenotypic analysis","volume":"20","author":"Lomax","year":"2017","journal-title":"Int J Rheum Dis"},{"key":"10.1016\/j.autrev.2020.102587_bb0295","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1001\/jamadermatol.2017.0581","article-title":"Pembrolizumab-induced extensive panniculitis and nevus regression: two novel cutaneous manifestations of the post-immunotherapy granulomatous reactions Spectrum","volume":"153","author":"Burillo-Martinez","year":"2017","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.autrev.2020.102587_bb0300","doi-asserted-by":"crossref","first-page":"e100","DOI":"10.1016\/j.jtho.2017.03.006","article-title":"Nivolumab-induced granulomatous inflammation of the pleura","volume":"12","author":"Benn","year":"2017","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.autrev.2020.102587_bb0305","first-page":"126","article-title":"Pembrolizumab reactivates pulmonary granulomatosis","volume":"22","author":"Al-dliw","year":"2017","journal-title":"Respir Med Case Rep"},{"key":"10.1016\/j.autrev.2020.102587_bb0310","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1513\/AnnalsATS.201611-863LE","article-title":"Sarcoidosis-like granulomatous lung reaction associated with anti-programmed death Receptor-1 ligand therapy","volume":"14","author":"Balestra","year":"2017","journal-title":"Ann ATS"},{"key":"10.1016\/j.autrev.2020.102587_bb0315","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.ejca.2016.12.038","article-title":"Programmed cell death protein-1 (PD-1) inhibitor therapy in patients with advanced melanoma and preexisting autoimmunity or ipilimumab-triggered autoimmunity","volume":"75","author":"Gutzmer","year":"2017","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.autrev.2020.102587_bb0320","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.ejca.2017.05.032","article-title":"Prevalence of immune-related systemic adverse events in patients treated with anti-programmed cell death 1\/anti-programmed cell death-ligand 1 agents: a single-Centre pharmacovigilance database analysis","volume":"82","author":"Le Burel","year":"2017","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.autrev.2020.102587_bb0325","first-page":"592","article-title":"Sarcoidosis-like granulomatous reaction associated with Pembrolizumab immunotherapy","volume":"54","author":"Gaya","year":"2018","journal-title":"Arch Bronconeumol"},{"key":"10.1016\/j.autrev.2020.102587_bb0330","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1097\/CMR.0000000000000437","article-title":"Sarcoid-like reactions in patients receiving modern melanoma treatment","volume":"28","author":"Dimitriou","year":"2018","journal-title":"Melanoma Res"},{"key":"10.1016\/j.autrev.2020.102587_bb0335","article-title":"Checkpoint inhibitor sarcoid reaction mimicking bone metastases","volume":"19","author":"Jeperson","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.autrev.2020.102587_bb0340","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1177\/1203475418776934","article-title":"Erythema Nodosum as the initial presentation of Nivolumab-induced sarcoidosis-like reaction","volume":"22","author":"Laroche","year":"2018","journal-title":"J Cutan Med Surg"},{"key":"10.1016\/j.autrev.2020.102587_bb0345","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1200\/JOP.2017.027383","article-title":"Pembrolizumab-related sarcoid-like reaction presenting as reactivation of quiescent scars","volume":"14","author":"Mckenna","year":"2018","journal-title":"J Oncol Pract"},{"key":"10.1016\/j.autrev.2020.102587_bb0350","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1097\/DAD.0000000000001066","article-title":"Granulomatous Tumoral melanosis associated with Pembrolizumab therapy\u00a0: a mimicker of disease progression in metastatic melanoma","volume":"40","author":"Woodbeck","year":"2018","journal-title":"Am J Dermatopathol"},{"key":"10.1016\/j.autrev.2020.102587_bb0355","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1148\/radiol.2018180572","article-title":"Pembrolizumab-induced sarcoid-like reactions during treatment of metastatic melanoma","volume":"289","author":"Cheshire","year":"2018","journal-title":"Radiology"},{"key":"10.1016\/j.autrev.2020.102587_bb0360","doi-asserted-by":"crossref","first-page":"e260","DOI":"10.1111\/jdv.14781","article-title":"Programmed cell death 1 blockade-induced cutaneous sarcoid-like granulomas in advanced melanoma: a case report","volume":"32","author":"Ogawa","year":"2018","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.autrev.2020.102587_bb0365","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1158\/2326-6066.CIR-17-0715","article-title":"Sarcoid-like granulomatosis of the lung related to immune checkpoint inhibitors: distinct clinical and imaging features of a unique immune-related adverse event","volume":"6","author":"Nishino","year":"2018","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.autrev.2020.102587_bb0370","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.autrev.2018.01.003","article-title":"Rheumatic manifestations among cancer patients treated with immune checkpoint inhibitors","volume":"17","author":"Lidar","year":"2018","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2020.102587_bb0375","doi-asserted-by":"crossref","first-page":"183","DOI":"10.2214\/AJR.17.19144","article-title":"A Sarcoidlike reaction mimicking metastatic malignancy in a patient with melanoma treated with Pembrolizumab","volume":"210","author":"Wesselius","year":"2018","journal-title":"Am J Roentgenol"},{"key":"10.1016\/j.autrev.2020.102587_bb0380","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1111\/cup.13307","article-title":"Pembrolizumab-induced sarcoidal infusion site reaction","volume":"45","author":"Smith","year":"2018","journal-title":"J Cutan Pathol"},{"key":"10.1016\/j.autrev.2020.102587_bb0385","doi-asserted-by":"crossref","first-page":"e519","DOI":"10.1097\/RLU.0000000000002724","article-title":"Nivolumab-associated pulmonary and bone sarcoidosis in a patient with melanoma of unknown primary","volume":"44","author":"Tulbah","year":"2019","journal-title":"Clin Nucl Med"},{"key":"10.1016\/j.autrev.2020.102587_bb0390","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1097\/RLU.0000000000002408","article-title":"Course of Pembrolizumab-associated multiorgan sarcoidosis","volume":"44","author":"Lu","year":"2019","journal-title":"Clin Nucl Med"},{"key":"10.1016\/j.autrev.2020.102587_bb0395","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1111\/cup.13569","article-title":"Granulomatous\/sarcoid-like reactions in the setting of programmed cell death-1 inhibition: a potencial mimic of disease recurrence","volume":"47","author":"Hiraki","year":"2020","journal-title":"J Cutan Pathol"},{"key":"10.1016\/j.autrev.2020.102587_bb0400","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1111\/bjd.12279","article-title":"Novel cutaneous effects of combination chemotherapy with BRAF and MEK inhibitors: a report of two cases","volume":"169","author":"Green","year":"2013","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.autrev.2020.102587_bb0405","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1111\/bjd.12268","article-title":"Sarcoidosis associated with vemurafenib","volume":"169","author":"Adam","year":"2013","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.autrev.2020.102587_bb0410","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1001\/jamadermatol.2013.7919","article-title":"Cutaneous granulomatous eruption and successful response to potent topical steroids in patients undergoing targeted BRAF inhibitor treatment for metastatic melanoma","volume":"150","author":"Park","year":"2014","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.autrev.2020.102587_bb0415","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1159\/000439400","article-title":"Sarcoidosis in patients treated with Vemurafenib for metastatic melanoma: a paradoxical autoimmune activation","volume":"23","author":"Lheure","year":"2015","journal-title":"Dermatology"},{"key":"10.1016\/j.autrev.2020.102587_bb0420","doi-asserted-by":"crossref","first-page":"e96","DOI":"10.1097\/DAD.0000000000000230","article-title":"Panniculitis with necrotizing granulomata in a patient on BRAF inhibitor (Dabrafenib) therapy for metastatic melanoma","volume":"37","author":"Ramani","year":"2015","journal-title":"Am J Dermatopathol"},{"key":"10.1016\/j.autrev.2020.102587_bb0425","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1097\/CMR.0000000000000186","article-title":"Granulomatous nephritis and dermatitis in a patient with BRAF V600E mutant metastatic melanoma treated with dabrafenib and trametinib","volume":"25","author":"Jansen","year":"2015","journal-title":"Melanoma Res"},{"key":"10.1016\/j.autrev.2020.102587_bb0430","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1097\/DAD.0000000000000281","article-title":"BRAF inhibitor\u2013induced Antitumoral granulomatous dermatitis eruption in advanced melanoma","volume":"37","author":"Garrido","year":"2015","journal-title":"Am J Dermatopathol"},{"key":"10.1016\/j.autrev.2020.102587_bb0435","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1111\/1346-8138.13255","article-title":"Cutaneous granulomatous panniculitis and sarcoidal granulomatous papular eruption in a patient with metastatic melanoma treated with a BRAF inhibitor","volume":"43","author":"Leal","year":"2016","journal-title":"J Dermatol"},{"key":"10.1016\/j.autrev.2020.102587_bb0440","doi-asserted-by":"crossref","first-page":"AB195","DOI":"10.1016\/j.jaad.2017.04.761","article-title":"Persistent granulomatous cutaneous drug eruption to a BRAF inhibitor","volume":"76","author":"Wali","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.autrev.2020.102587_bb0445","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1097\/DAD.0000000000001276","article-title":"BRAF inhibitor-associated granulomatous dermatitis: a report of 3 cases","volume":"41","author":"Hui Ong","year":"2019","journal-title":"Am J Dermatopathol"},{"key":"10.1016\/j.autrev.2020.102587_bb0450","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1159\/000499959","article-title":"Granulomatous reactions from tattoos following BRAF inhibitor therapy","volume":"11","author":"Giet","year":"2019","journal-title":"Case Rep Dermatol"},{"key":"10.1016\/j.autrev.2020.102587_bb0455","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1016\/j.jtho.2018.04.031","article-title":"Sarcoidosis-like reactions induced by checkpoint inhibitors","volume":"13","author":"Gkiozos","year":"2018","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.autrev.2020.102587_bb0460","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000007595","article-title":"Multidisciplinary approach and long-term follow-up in a series of 640 consecutive patients with sarcoidosis: cohort study of a 40-year clinical experience at a tertiary referral center in Barcelona, Spain","volume":"96","author":"Ma\u00f1\u00e1","year":"2017","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.autrev.2020.102587_bb0465","first-page":"102456","article-title":"Mechanistic classification of immune checkpoint inhibitor toxicity as a pointer to minimal treatment strategies to further improve survival","volume":"12","author":"McGonagle","year":"2019","journal-title":"Autoimmun Rev"}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997220301518?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997220301518?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T21:20:03Z","timestamp":1761600003000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568997220301518"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8]]},"references-count":93,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2020,8]]}},"alternative-id":["S1568997220301518"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2020.102587","relation":{},"ISSN":["1568-9972"],"issn-type":[{"value":"1568-9972","type":"print"}],"subject":[],"published":{"date-parts":[[2020,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Sarcoidosis related to checkpoint and BRAF\/MEK inhibitors in melanoma","name":"articletitle","label":"Article Title"},{"value":"Autoimmunity Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.autrev.2020.102587","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"102587"}}